Boehringer reports positive safety profile of Jardiance for type 2 diabetes

Boehringer Ingelheim has reported a positive safety profile of oral Jardiance (empagliflozin) for the treatment of adults with type 2 diabetes.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news